Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> Anticoagulation thresholds suggested by such tools are not definitive indicators of requirement for anticoagulation [B]. <br><br>
<sup>2</sup> Inform pts that stroke risk can potentially be reduced w/ antithrombotics but that major bleeding risk may ↑ [B]. Judgment/preferences play an important role in weighing potential risks/benefits [B].
<br><br>
<sup>3</sup> Risk-benefit ratio of oral anticoagulants is uncertain in pts with mod-severe dementia or very frequent falls [B]. Data are insufficient to determine whether anticoagulants are safe or effective in elderly pts who have frequent falls or advanced dementia. An elderly pt would need to fall 295 times in 1y to offset stroke-reduction benefits w/ warfarin.
<br><br>
<sup>4</sup> The new oral anticoagulants have a more favorable intracranial bleeding profile vs warfarin (dabigatran 150 mg bid: RR 0.40; rivaroxaban 20 mg daily: HR 0.67; apixaban 5 mg bid: HR 0.42).
<br><br>
<sup>5</sup> There are currently no clinical recommendations for the use of oral anticoagulants in NVAF w/ ESRD [U].
<br><br>
<sup>6</sup> In pts w/ NVAF, GI bleeding was greater w/ dabigatran 150 mg bid as compared w/ warfarin (1.51%/y). GI bleeding occurred more frequently w/ rivaroxaban vs warfarin, as did bleeding that led to ↓Hgb or required transfusion. GI bleeding was nonsignificantly less w/ apixaban vs warfarin (0.86%/y).
<sup>2</sup> Inform pts that stroke risk can potentially be reduced w/ antithrombotics but that major bleeding risk may ↑ [B]. Judgment/preferences play an important role in weighing potential risks/benefits [B].
<br><br>
<sup>3</sup> Risk-benefit ratio of oral anticoagulants is uncertain in pts with mod-severe dementia or very frequent falls [B]. Data are insufficient to determine whether anticoagulants are safe or effective in elderly pts who have frequent falls or advanced dementia. An elderly pt would need to fall 295 times in 1y to offset stroke-reduction benefits w/ warfarin.
<br><br>
<sup>4</sup> The new oral anticoagulants have a more favorable intracranial bleeding profile vs warfarin (dabigatran 150 mg bid: RR 0.40; rivaroxaban 20 mg daily: HR 0.67; apixaban 5 mg bid: HR 0.42).
<br><br>
<sup>5</sup> There are currently no clinical recommendations for the use of oral anticoagulants in NVAF w/ ESRD [U].
<br><br>
<sup>6</sup> In pts w/ NVAF, GI bleeding was greater w/ dabigatran 150 mg bid as compared w/ warfarin (1.51%/y). GI bleeding occurred more frequently w/ rivaroxaban vs warfarin, as did bleeding that led to ↓Hgb or required transfusion. GI bleeding was nonsignificantly less w/ apixaban vs warfarin (0.86%/y).
Detail Type
Text
Detail Text
Patient Type Detail Header (Long)
Use risk stratification scheme<sup>1</sup> to determine risk level